A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.
作者
Mark J. Levis,Mehdi Hamadani,Brent R. Logan,Matt Rosales,Alexander E. Perl,Steven Michael Devine,Erkut Bahceci,Yi-Bin Albert Chen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins] 日期:2018-05-20卷期号:36 (15_suppl): TPS7075-TPS7075被引量:21
标识
DOI:10.1200/jco.2018.36.15_suppl.tps7075
摘要
TPS7075 Background: Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in acute myeloid leukemia (AML) are a common indication for allogeneic hematopoietic stem cell transplant (HSCT) in first complete remission (CR1). Despite HSCT, relapses are common and cure rates are limited thereafter. The use of FLT3 inhibitors as post-HSCT maintenance therapy has not been prospectively evaluated. Gilteritinib is a highly selective, potent FLT3/AXL inhibitor with robust activity and favorable tolerability in relapsed/refractory AML. Several gilteritinib trials in AML include single arm post-HSCT gilteritinib maintenance therapy to establish the feasibility of this strategy. This trial will compare the safety and efficacy of 2-year maintenance therapy with gilteritinib versus placebo in patients with FLT3-ITD+ AML in CR1 after allogeneic HSCT. Methods: This Phase 3, randomized, double-blind, placebo-controlled multicenter trial (NCT02997202; Blood and Marrow Transplant Clinical Trials Network Protocol 1506), to be conducted at 149 sites worldwide, will enroll 532 adult subjects (aged ≥18 years) with FLT3-ITD+ AML in CR1 who are ≥30 days and ≤90 days from scheduled allogeneic HSCT. Of these 532 subjects, 346 subjects who have achieved successful engraftment without uncontrolled graft-versus-host disease (GVHD) or other serious toxicity will be randomized (1:1; stratified by conditioning regimen intensity, time from HSCT [Day 0] to randomization [30–60 days vs 61–90 days], and presence of minimal residual disease [MRD] in the pre-transplant bone marrow sample) to receive oral gilteritinib (120 mg) or matching placebo as maintenance therapy for 2 years. The primary endpoint is relapse-free survival (RFS) in the two treatment arms; RFS will be assessed from the time of randomization to the time of death or morphologic leukemia relapse (as defined by Revised IWG criteria). Overall survival is a key secondary endpoint. Other endpoints include safety/tolerability, non-relapse mortality, event-free survival, incidences of acute/chronic GVHD, and MRD. As of January 30, 2018, 47 patients have been enrolled and 11 have been randomized. Clinical trial information: NCT02997202.